Hemolysis clinical trials

Explore recruiting hemolysis clinical trials.

Recruiting hemolysis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hemolysis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of OMS906 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Spain, Romania, Italy, Hungary, Greece, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Ravulizumab dose optimization

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

HEMolyse and Organ damage imPROvement in sickle cell disease by VoxElotor. An open-label one stage phase II design.HEMOPROVE

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An open label, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have completed PNH Phase 2 and Phase 3 studies with iptacopan.

Germany, Italy, Czechia, France, Spain, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.

Netherlands, Germany, Belgium, France, Italy

Phase II and Phase III (Integrated) EU CTIS Study details

Hemolysis trials by city

Hemolysis in Toronto Hemolysis in Vancouver Hemolysis in Montreal Hemolysis in Calgary Hemolysis in Edmonton Hemolysis in Ottawa Hemolysis in Winnipeg Hemolysis in Quebec City Hemolysis in Hamilton Hemolysis in Kitchener Hemolysis in London Hemolysis in Halifax Hemolysis in New York Hemolysis in Los Angeles Hemolysis in Chicago Hemolysis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease